Patrick Sorn

Patrick Sorn

Auto-generated profile, based on publicly available information

Patrick Sorn

TRON—Translational Oncology at the University Medical Center of Johannes Gutenberg University Mainz gGmbH , Mainz 55131, Germany

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Bioinformatics Advances
Verified
Journal Article
Open access
PDF file
FLFranziska Lang
Franziska Lang
PSPatrick Sorn
Patrick Sorn
MSMartin Suchan
Martin Suchan
AHAlina Henrich
Alina Henrich
CAChristian Albrecht
Christian Albrecht
JIJonas Ibn-Salem
Jonas Ibn-Salem
Neoantigens are promising targets for cancer immunotherapies and might arise from alternative splicing. However, detecting tumor-specific splicing is challenging because many non-canonical splice junctions identified in tumors also appear in healthy tissues. To increase tumor-specificity, we focused on splicing caused by somatic mutations as a source for neoantigen candidates in individual patients. We developed the tool splice2neo with multiple functionalities to integrate predicted splice effects from somatic mutations with splice junctions detected in tumor RNA-seq and to annotate the resulting transcript and peptide sequences. Additionally, we provide the tool EasyQuant for targeted RNA-seq read mapping to candidate splice junctions. Using a stringent detection rule, we predicted 1.7 splice junctions per patient as splice targets with a false discovery rate below 5% in a melanoma cohort. We confirmed tumor-specificity using independent, healthy tissue samples. Furthermore, using tumor-derived RNA, we confirmed individual exon-skipping events experimentally. Most target splice junctions encoded neoepitope candidates with predicted MHC-I or MHC-II binding. Compared to neoepitope candidates from non-synonymous point mutations, the splicing-derived MHC-I neoepitope candidates had lower self-similarity to corresponding wild-type peptides. In conclusion, we demonstrate that identifying mutation-derived, tumor-specific splice junctions can lead to additional neoantigen candidates to expand the target repertoire for cancer immunotherapies. The R package splice2neo and the python package EasyQuant are available at https://github.com/TRON-Bioinformatics/splice2neo and https://github.com/TRON-Bioinformatics/easyquant, respectively. Supplementary data are available at Bioinformatics Advances online.

29 June 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
FLFranziska Lang
Franziska Lang
PSPatrick Sorn
Patrick Sorn
MSMartin Suchan
Martin Suchan
AHAlina Henrich
Alina Henrich
CAChristian Albrecht
Christian Albrecht
JIJonas Ibn-Salem
Jonas Ibn-Salem
Splicing is dysregulated in many tumors and may result in tumor-specific transcripts that can encode neoantigens, which are promising targets for cancer immunotherapy. Detecting tumor-specific splicing is challenging because many non-canonical splice junctions identified in tumor transcriptomes also appear in healthy tissues. Here, we developed splice2neo to integrate the predicted splice effects from somatic mutations with splice junctions detected in tumor RNA-seq for individual cancer patients. Splice2neo excludes splice junctions from healthy tissue samples, annotates resulting transcript and peptide sequences, and provides targeted re-quantification of supporting RNA-seq reads. We developed a stringent detection rule to predict splice junctions as mutation-derived targets and identified 1.7 target splice junctions per tumor with a false discovery rate below 5% in a melanoma cohort. We confirmed tumor-specificity using independent, healthy tissue samples. Furthermore, using tumor-derived RNA, we confirmed individual exon skipping events experimentally. Most target splice junctions encoded neoepitope candidates with predicted MHC-I or MHC-II binding. Compared to neoepitope candidates derived from non-synonymous point mutations, the splicing-derived MHC-I neoepitope candidates had a lower self-similarity to corresponding wild-type peptides. In conclusion, we demonstrate that identifying mutation-derived and tumor-specific splice junctions can lead to additional neoantigen candidates to expand the target repertoire for cancer immunotherapies. Key Points: splice2neo is a versatile tool for identifying and analyzing of splice junctions as a source of neoantigen candidates We identified mutation-retrieved splice junctions supported by RNA-seq in melanoma samples The predicted target splice junctions exhibited a strong tumor-specificity as they were absent in healthy tissues. Target splice junctions often lead to frame-shift peptides and encode promising neoantigen candidates